Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (BRTX) was submitted on November 16, 2021, with the report dated November 18, 2021. The filing addresses corporate governance actions taken following a 1-for-4,000 reverse stock split that was effected on October 27, 2021.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly a current report regarding amendments to the Company's Articles of Incorporation.
Material Changes
- Authorized Shares Reduction: The Board of Directors approved a reduction in the number of authorized common shares from 300,000,000,000 to 75,000,000.
- Regulatory Filing: A Certificate of Amendment was filed with the Secretary of State of Delaware on November 16, 2021, to formalize the reduction.
- Context: The reduction aligns with the 1-for-4,000 reverse split ratio executed in October 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It is a procedural filing to document the change in authorized capital structure.
Investor Verification Checklist
- Verify the effective date of the 1-for-4,000 reverse split (October 27, 2021) and its impact on share count.
- Confirm the new authorized share cap of 75,000,000 via the Delaware Secretary of State records.
- Review the attached Exhibit 3.1 (Certificate of Amendment) for specific legal language regarding the capital structure change.